Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Alvotech ( (ALVO) ) just unveiled an announcement.
On October 6, 2025, Alvotech announced that the European Medicines Agency accepted a Marketing Authorization Application for AVT23, a proposed biosimilar to Xolair®, developed in collaboration with Kashiv BioSciences LLC. This milestone, in partnership with Advanz Pharma, marks a significant step towards expanding access to affordable biologic medicines for patients in Europe and other regions, potentially enhancing Alvotech’s industry positioning and stakeholder value.
The most recent analyst rating on (ALVO) stock is a Hold with a $8.50 price target. To see the full list of analyst forecasts on Alvotech stock, see the ALVO Stock Forecast page.
Spark’s Take on ALVO Stock
According to Spark, TipRanks’ AI Analyst, ALVO is a Neutral.
Alvotech’s overall stock score reflects a balance of strong earnings call performance and strategic growth initiatives against financial instability and high valuation. The company’s improving profitability and market expansion are positive, but financial risks and valuation concerns weigh on the score.
To see Spark’s full report on ALVO stock, click here.
More about Alvotech
Alvotech is a global biotech company focused on developing and manufacturing biosimilar medicines. Founded by Robert Wessman, the company aims to be a leader in the biosimilar space by offering high-quality, cost-effective products and services. Alvotech has a comprehensive development pipeline targeting autoimmune disorders, eye disorders, osteoporosis, respiratory disease, and cancer, and has established strategic commercial partnerships across the globe to leverage local expertise.
Average Trading Volume: 392,314
Technical Sentiment Signal: Sell
Current Market Cap: $2.51B
Learn more about ALVO stock on TipRanks’ Stock Analysis page.